I view ETSY like Pintrust. I don't use either but think them useful good ideas and PINS has done great for us although we dipped too early.
GBA Presents: House of Gummy-!
- Thread starter stonedinvestor
- Start date
Should we start an entirely new thread on jan 1?
A24-- Answers 24' or GBA Presents: YEAR24' STOCKS
A24-- Answers 24' or GBA Presents: YEAR24' STOCKS
I have a really interesting list so far that has zero big tech.
Don't hold me to it, but I almost feel slightly better today. If I get through this without a Hospital stay it will be my own Christmas miracle.
Don't hold me to it, but I almost feel slightly better today. If I get through this without a Hospital stay it will be my own Christmas miracle.
After the bell)))))))))))
Arcutis Biotherapeutics announces FDA approval of NDA for ZORYVE topical foam » 17:13 ARQT
Blink Charging +4% in extended trade after Ken Griffin's Citadel discloses passive stake
BLNK-2.17%
Arcutis Biotherapeutics announces FDA approval of NDA for ZORYVE topical foam » 17:13 ARQT
Blink Charging +4% in extended trade after Ken Griffin's Citadel discloses passive stake
BLNK-2.17%
ABBV did not do much last week at all. That's ok because I have not bought it!
How about ABBV & CFLT for the acct with Big Pete? I like that.
Two big business-development deals appear to have renewed investors' interest in AbbVie. On Nov. 30, the company announced plans to buyImmunoGenfor $10.1 billion. A week later, AbbVie revealed that it intends to acquireCerevel Therapeuticsfor $8.7 billion. Both transactions appear to be smart moves that will bolster AbbVie's pipeline and, in the case of ImmunoGen, add an approved cancer therapy with fast-growing sales to its lineup.
Speaking of cancer therapies, investors also have a reason to be optimistic about AbbVie's epcoritamab. The drugmaker recently announced positive results for the experimental bispecific antibody in a phase 1/2 study for treating relapsed/refractory follicular lymphoma. The therapy has already been approved in both the United States and the European Union in treating certain types of large B-cell lymphoma. Analysts project that epcoritamab could generate peak annual sales of close to $3 billion.
I also think that the increasing prospects of interest-rate cuts next year could entice some income investors to shift money into AbbVie stock. Lower rates will cause bond yields to fall, but could provide a catalyst for stocks. AbbVie's current dividend yield of 4% and its status as a Dividend King could be a winning combination for income investors seeking better alternatives to bonds.
How about ABBV & CFLT for the acct with Big Pete? I like that.
Two big business-development deals appear to have renewed investors' interest in AbbVie. On Nov. 30, the company announced plans to buyImmunoGenfor $10.1 billion. A week later, AbbVie revealed that it intends to acquireCerevel Therapeuticsfor $8.7 billion. Both transactions appear to be smart moves that will bolster AbbVie's pipeline and, in the case of ImmunoGen, add an approved cancer therapy with fast-growing sales to its lineup.
Speaking of cancer therapies, investors also have a reason to be optimistic about AbbVie's epcoritamab. The drugmaker recently announced positive results for the experimental bispecific antibody in a phase 1/2 study for treating relapsed/refractory follicular lymphoma. The therapy has already been approved in both the United States and the European Union in treating certain types of large B-cell lymphoma. Analysts project that epcoritamab could generate peak annual sales of close to $3 billion.
I also think that the increasing prospects of interest-rate cuts next year could entice some income investors to shift money into AbbVie stock. Lower rates will cause bond yields to fall, but could provide a catalyst for stocks. AbbVie's current dividend yield of 4% and its status as a Dividend King could be a winning combination for income investors seeking better alternatives to bonds.
Wharton Professor Jeremy Siegel's 2024 outlook: Stocks and home prices will jump, interest rates will tumble, and recession won't hit and Stoney's health will improve.
- The "Wizard of Wharton" expects value and small stocks to outpace the "Magnificent Seven" next year.
benchmark S&P 500 index has rallied 23% this year to trade at 4,720 points as of Thursday's close — just 2% below its all-time intraday high of 4,819 points in January 2022.
As we approach old highs we must be aware of whiplash. Here is where the Professor and I diverge.
"I think we may have five or six rate cuts," Siegel said about the outlook for next year, basing his prediction on inflation slowing and commodity prices dropping in recent months...
And here is where the Professor was clearly drunk. We will not be getting 5 or 6 rate cuts.
and really the disappointment for the market will be formulated off this miscalculation so sooner the better we have to get our heads around higher for longer and around June a 1st cut of .50
As we approach old highs we must be aware of whiplash. Here is where the Professor and I diverge.
"I think we may have five or six rate cuts," Siegel said about the outlook for next year, basing his prediction on inflation slowing and commodity prices dropping in recent months...
And here is where the Professor was clearly drunk. We will not be getting 5 or 6 rate cuts.
and really the disappointment for the market will be formulated off this miscalculation so sooner the better we have to get our heads around higher for longer and around June a 1st cut of .50
ABE-----> Anything But Etsy.
CHILDREN OF THE STOCK REVOLUTION WHAT ARE WE GOING TO DO?
IT TAKES SOME BALLS TO GIVE UP ON THE #1 STOCK THREAD IN AMERICA...
BUT SHOULDN'T WE MOVE ON IN THE NEW YEAR?
IT TAKES SOME BALLS TO GIVE UP ON THE #1 STOCK THREAD IN AMERICA...
BUT SHOULDN'T WE MOVE ON IN THE NEW YEAR?